Urticaria
Özet
This chapter elucidates the specific diagnostic, classification, and therapeutic management paradigms for urticaria within the geriatric population (individuals aged 60 and over). Demographic shifts necessitate a nuanced understanding of urticarial pathophysiology and its clinical course in this patient cohort. Urticaria, a mast cell-mediated dermatosis characterized by wheals and/or angioedema, is classified based on etiology as Chronic Spontaneous (CSU) or Chronic Inducible (CIndU).
The text scrutinizes the etiopathogenesis of CSU and the heightened prevalence of concomitant autoimmune and neoplastic comorbidities in this demographic. Therapeutic interventions are complicated by polypharmacy and the distinct pharmacokinetic and pharmacodynamic alterations inherent to aging. The treatment algorithm positions second-generation H1 antihistamines as the first-line intervention, reserving omalizumab, an anti-IgE monoclonal antibody, for refractory cases. This review underscores the imperative for meticulous assessment of drug-drug interactions and the optimization of individualized therapeutic protocols for geriatric patients with urticaria.
Referanslar
Nations U. World Population Ageing 2019 (st/esa/ser. a/444). United Nations New York City, NY, USA; 2020.
WHO. Ageing. 2023. [updated 5 Jan. Available from: https://www.who.int/health-topics/ageing#tab=tab_1.
Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-66.
Maurer M, Zuberbier T, Metz M. The classification, pathogenesis, diagnostic workup, and management of urticaria: an update. Allergic Diseases–From Basic Mechanisms to Comprehensive Management and Prevention: Springer; 2021. p. 117-33.
Magerl M, Altrichter S, Borzova E, Giménez‐Arnau A, Grattan C, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias–The EAACI/GA 2 LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71(6):780-802.
Kolkhir P, Giménez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nature Reviews Disease Primers. 2022;8(1):61.
Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CE, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71(6):780-802.
Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2011;66(3):317-30.
Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol. 2010;35(8):869-73.
Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy. 2020;75(2):423-32.
Gaig P, Olona M, Muñoz Lejarazu D, Caballero MT, Domínguez FJ, Echechipia S, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol. 2004;14(3):214-20.
Nava FV, Burnes JM. Prevalence and factors associates to chronic urticaria. Analysis of the allergic rhinitis and symptoms related to asthma as a factors associated to chronic urticaria in a urban area of northeastern of Mexico. Alergologia e inmunologia clinica. 2004;19(1):16-24.
Balp MM, Lopes da Silva N, Vietri J, Tian H, Ensina LF. The Burden of Chronic Urticaria from Brazilian Patients' Perspective. Dermatol Ther (Heidelb). 2017;7(4):535-45.
Vietri J, Turner SJ, Tian H, Isherwood G, Balp MM, Gabriel S. Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey. Ann Allergy Asthma Immunol. 2015;115(4):306-11.
Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, Ben-Shoshan M, Bernstein JA, Ensina LF, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184(2):226-36.
Wertenteil S, Strunk A, Garg A. Prevalence estimates for chronic urticaria in the United States: A sex- and age-adjusted population analysis. J Am Acad Dermatol. 2019;81(1):152-6.
Chen YJ, Wu CY, Shen JL, Chen TT, Chang YT. Cancer risk in patients with chronic urticaria: a population-based cohort study. Arch Dermatol. 2012;148(1):103-8.
Weller K, Maurer M, Bauer A, Wedi B, Wagner N, Schliemann S, et al. Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany. J Eur Acad Dermatol Venereol. 2022;36(1):91-9.
Napolitano M, Fabbrocini G, Stingeni L, Patruno C. Prevalence of chronic inducible urticaria in elderly patients. Journal of Clinical Medicine. 2021;10(2):247.
Ban GY, Kim MY, Yoo HS, Nahm DH, Ye YM, Shin YS, et al. Clinical features of elderly chronic urticaria. Korean J Intern Med. 2014;29(6):800-6.
Magen E, Mishal J, Schlesinger M. Clinical and laboratory features of chronic idiopathic urticaria in the elderly. Int J Dermatol. 2013;52(11):1387-91.
Chuamanochan M, Kulthanan K, Tuchinda P, Chularojanamontri L, Nuchkull P. Clinical features of chronic urticaria in aging population. Asian Pacific journal of allergy and immunology. 2016;34(3).
Juhlin L. Recurrent urticaria: clinical investigation of 330 patients. Br J Dermatol. 1981;104(4):369-81.
Ventura MT, Cassano N, Romita P, Vestita M, Foti C, Vena GA. Management of chronic spontaneous urticaria in the elderly. Drugs & Aging. 2015;32:271-82.
Ventura MT, Napolitano S, Buquicchio R, Cecere R, Arsieni A. An approach to urticaria in the elderly patients. Immunopharmacol Immunotoxicol. 2012;34(3):530-3.
Guillet G, Bécherel PA, Pralong P, Delbarre M, Outtas O, Martin L, et al. The burden of chronic urticaria: French baseline data from the international real-life AWARE study. Eur J Dermatol. 2019;29(1):49-54.
Maurer M, Houghton K, Costa C, Dabove F, Ensina LF, Giménez-Arnau A, et al. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. World Allergy Organ J. 2018;11(1):32.
Lee N, Lee JD, Lee HY, Kang DR, Ye YM. Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010-2014. Allergy Asthma Immunol Res. 2017;9(5):438-45.
Lee SJ, Ha EK, Jee HM, Lee KS, Lee SW, Kim MA, et al. Prevalence and Risk Factors of Urticaria With a Focus on Chronic Urticaria in Children. Allergy Asthma Immunol Res. 2017;9(3):212-9.
Broder MS, Raimundo K, Antonova E, Chang E. Resource use and costs in an insured population of patients with chronic idiopathic/spontaneous urticaria. Am J Clin Dermatol. 2015;16(4):313-21.
Weller K, Altrichter S, Ardelean E, Krause K, Magerl M, Metz M, et al. [Chronic urticaria. Prevalence, course, prognostic factors and impact]. Hautarzt. 2010;61(9):750-7.
Eun SJ, Lee JY, Kim DY, Yoon HS. Natural course of new-onset urticaria: Results of a 10-year follow-up, nationwide, population-based study. Allergol Int. 2019;68(1):52-8.
Church MK, Kolkhir P, Metz M, Maurer M. The role and relevance of mast cells in urticaria. Immunol Rev. 2018;282(1):232-47.
Techasatian L, Phungoen P, Chaiyarit J, Uppala R. Etiological and predictive factors of pediatric urticaria in an emergency context. BMC pediatrics. 2021;21:1-6.
Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nature medicine. 2012;18(5):693-704.
Ying S, Kikuchi Y, Meng Q, Kay AB, Kaplan AP. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol. 2002;109(4):694-700.
Kay AB, Ying S, Ardelean E, Mlynek A, Kita H, Clark P, et al. Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with low-level persistence in uninvolved skin. Br J Dermatol. 2014;171(3):505-11.
Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135(2):337-42.
Asai K, Kitaura J, Kawakami Y, Yamagata N, Tsai M, Carbone DP, et al. Regulation of mast cell survival by IgE. Immunity. 2001;14(6):791-800.
Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunologic research. 2006;34:97-115.
Kolkhir P, Elieh-Ali-Komi D, Metz M, Siebenhaar F, Maurer M. Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. Nature Reviews Immunology. 2022;22(5):294-308.
Giménez-Arnau AM, de Montjoye L, Asero R, Cugno M, Kulthanan K, Yanase Y, et al. The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(6):2195-208.
Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R. Expression of tissue factor by eosinophils in patients with chronic urticaria. International archives of allergy and immunology. 2009;148(2):170-4.
Tedeschi A, Kolkhir P, Asero R, Pogorelov D, Olisova O, Kochergin N, et al. Chronic urticaria and coagulation: pathophysiological and clinical aspects. Allergy. 2014;69(6):683-91.
Cugno M, Borghi A, Garcovich S, Marzano AV. Coagulation and skin autoimmunity. Frontiers in Immunology. 2019;10:1407.
Karra L, Berent-Maoz B, Ben-Zimra M, Levi-Schaffer F. Are we ready to downregulate mast cells? Current opinion in immunology. 2009;21(6):708-14.
Konstantinou GN, Asero R, Ferrer M, Knol EF, Maurer M, Raap U, et al. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy. 2013;68(1):27-36.
Sabroe RA, Fiebiger E, Francis DM, Maurer D, Seed PT, Grattan CE, et al. Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol. 2002;110(3):492-9.
Altrichter S, Peter HJ, Pisarevskaja D, Metz M, Martus P, Maurer M. IgE mediated autoallergy against thyroid peroxidase--a novel pathomechanism of chronic spontaneous urticaria? PLoS One. 2011;6(4):e14794.
Schmetzer O, Lakin E, Topal FA, Preusse P, Freier D, Church MK, et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;142(3):876-82.
Zuberbier T, Iffländer J, Semmler C, Henz BM. Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol. 1996;76(4):295-7.
Maurer M, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H, Giménez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005-16.
Khaliliya R, Confino-Cohen R, Lachover-Roth I, Meir-Shafrir K, Cohen-Engler A, Rosman Y. Chronic urticaria in elderly—new insights. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(4):1290-4.
Jáuregui Presa I, Navajas Rodríguez B, Ramos Bareño B, Gamboa Setién PM, Urrutia Etxebarria I, Antépara Ercoreca I. Chronic urticaria in special populations: children, pregnancy, lactation and elderly people. Current Treatment Options in Allergy. 2016;3:423-38.
Maurer M, Magerl M, Metz M, Siebenhaar F, Weller K, Krause K. Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy. 2013;68(6):816-9.
Makani H, Messerli FH, Romero J, Wever-Pinzon O, Korniyenko A, Berrios RS, et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol. 2012;110(3):383-91.
Pigman EC, Scott JL. Angioedema in the emergency department: the impact of angiotensin-converting enzyme inhibitors. The American journal of emergency medicine. 1993;11(4):350-4.
Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension. 2008;51(1):141-7.
Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol. 2003;3(3):311-7.
Aronow WS. Office management of hypertension in older persons. Am J Med. 2011;124(6):498-500.
Byrd JB, Shreevatsa A, Putlur P, Foretia D, McAlexander L, Sinha T, et al. Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. J Allergy Clin Immunol. 2007;120(2):403-8.
Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54(3):516-23.
Caballero T, Pedrosa M. Angioedema due to ACE Inhibitors. Current Treatment Options in Allergy. 2016;3:401-15.
Sánchez-Borges M, Ansotegui IJ, Baiardini I, Bernstein J, Canonica GW, Ebisawa M, et al. The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organization Journal. 2021;14(6):100533.
Kim BR, Yang S, Choi JW, Choi CW, Youn SW. Epidemiology and comorbidities of patients with chronic urticaria in Korea: a nationwide population‐based study. The Journal of dermatology. 2018;45(1):10-6.
Kolkhir P, Borzova E, Grattan C, Asero R, Pogorelov D, Maurer M. Autoimmune comorbidity in chronic spontaneous urticaria: a systematic review. Autoimmunity reviews. 2017;16(12):1196-208.
Kolkhir P, Altrichter S, Asero R, Daschner A, Ferrer M, Giménez-Arnau A, et al. Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria. Allergy Asthma Immunol Res. 2021;13(4):545-59.
Ramos-Casals M, Garcia-Carrasco M, Brito M, Lopez-Soto A, Font J. Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. Lupus. 2003;12(5):341-55.
Chiu HY, Muo CH, Sung FC. Associations of chronic urticaria with atopic and autoimmune comorbidities: a nationwide population-based study. Int J Dermatol. 2018;57(7):822-9.
Zazzali JL, Broder MS, Chang E, Chiu MW, Hogan DJ. Cost, utilization, and patterns of medication use associated with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012;108(2):98-102.
Lee HC, Hong JB, Chu CY. Chronic idiopathic urticaria in Taiwan: a clinical study of demographics, aggravating factors, laboratory findings, serum autoreactivity and treatment response. J Formos Med Assoc. 2011;110(3):175-82.
Shalom G, Magen E, Dreiher J, Freud T, Bogen B, Comaneshter D, et al. Chronic urticaria and atopic disorders: a cross-sectional study of 11 271 patients. Br J Dermatol. 2017;177(4):e96-e7.
Kim BR, Yang S, Choi JW, Choi CW, Youn SW. Epidemiology and comorbidities of patients with chronic urticaria in Korea: A nationwide population-based study. J Dermatol. 2018;45(1):10-6.
Alen Coutinho I, Regateiro FS, Fernandes RA, Pita JS, Gomes R, Coelho C, et al. Refractory chronic urticaria in adults: clinical characterization and predictors of severity. Allergy Asthma Clin Immunol. 2020;16(1):97.
Netchiporouk E, Sasseville D, Moreau L, Habel Y, Rahme E, Ben-Shoshan M. Evaluating Comorbidities, Natural History, and Predictors of Early Resolution in a Cohort of Children With Chronic Urticaria. JAMA Dermatol. 2017;153(12):1236-42.
Ghazanfar MN, Kibsgaard L, Thomsen SF, Vestergaard C. Risk of comorbidities in patients diagnosed with chronic urticaria: A nationwide registry-study. World Allergy Organ J. 2020;13(1):100097.
Asero R. Omalizumab in severe chronic urticaria: are slow and non-responders different? Eur Ann Allergy Clin Immunol. 2021;53(6):263-6.
Młynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63(6):777-80.
Stull D, Mcbride, D., Georgiou, P., Zuberbier, T., Grattan, C., & Balp, MM. Measuring patient severity in chronic spontaneous/idiopathic urticaria (CSU/CIU) as categorical health states: efficient and informative? Allergy. 2014;69:317.
Weller K, Groffik A, Church MK, Hawro T, Krause K, Metz M, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133(5):1365-72, 72.e1-6.
Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerra L, Compalati E, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU‐Q2oL). Allergy. 2005;60(8):1073-8.
Weller K, Magerl M, Peveling‐Oberhag A, Martus P, Staubach P, Maurer M. The Angioedema Quality of Life Questionnaire (AE‐QoL)–assessment of sensitivity to change and minimal clinically important difference. Allergy. 2016;71(8):1203-9.
Ahsan DM, Altrichter S, Gutsche A, Bernstein JA, Altunergil T, Brockstaedt M, et al. Development of the Cold Urticaria Activity Score. Allergy. 2022;77(8):2509-19.
Koch K, Weller K, Werner A, Maurer M, Altrichter S. Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria. Journal of Allergy and Clinical Immunology. 2016;138(5):1483-5. e9.
Ruft J, Asady A, Staubach P, Casale T, Sussmann G, Zuberbier T, et al. Development and validation of the cholinergic Urticaria quality‐of‐life questionnaire (CholU‐QoL). Clinical & Experimental Allergy. 2018;48(4):433-44.
Kulthanan K, Chiawsirikajorn Y, Jiamton S. Acute urticaria: etiologies, clinical course and quality of life. Asian Pacific journal of allergy and immunology. 2008;26(1):1.
Magen E, Zueva E, Mishal J, Schlesinger M, editors. The clinical and laboratory characteristics of acute spontaneous urticaria and its progression to chronic spontaneous urticaria. Allergy & Asthma Proceedings; 2016.
Tanaka T, Hiragun M, Hide M, Hiragun T. Analysis of primary treatment and prognosis of spontaneous urticaria. Allergology International. 2017;66(3):458-62.
Lin Y-R, Liu T-H, Wu T-K, Chang Y-J, Chou C-C, Wu H-P. Predictive factors of the duration of a first-attack acute urticaria in children. The American journal of emergency medicine. 2011;29(8):883-9.
Maurer M, Staubach P, Raap U, Richter‐Huhn G, Baier‐Ebert M, Chapman‐Rothe N. ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real‐life clinical practice. British Journal of Dermatology. 2016;174(4):892-4.
Balp M-M, Halliday AC, Severin T, Leonard SA, Partha G, Kalra M, et al. Clinical remission of chronic spontaneous urticaria (CSU): a targeted literature review. Dermatology and Therapy. 2022;12(1):15-27.
Curto-Barredo L, Riba Archilla L, Roura Vives G, Pujol Vallverdú RM, Giménez Arnau AM. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment. Acta Dermato-Venereologica 2018 Jul 11; 98 (7): 641-7. 2018.
Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. Journal of the American Academy of Dermatology. 2001;45(3):387-91.
Kolkhir P, André F, Church M, Maurer M, Metz M. Potential blood biomarkers in chronic spontaneous urticaria. Clinical & Experimental Allergy. 2017;47(1):19-36.
Toubi E, Kessel A, Avshovich N, Bamberger E, Sabo E, Nusem D, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy. 2004;59(8):869-73.
Deza G, Ricketti PA, Giménez-Arnau AM, Casale TB. Emerging biomarkers and therapeutic pipelines for chronic spontaneous urticaria. The Journal of Allergy and Clinical Immunology: In Practice. 2018;6(4):1108-17.
Sánchez‐Borges M, Caballero‐Fonseca F, Capriles‐Hulett A, González‐Aveledo L, Maurer M. Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology. 2017;31(6):964-71.
Stepaniuk P, Kan M, Kanani A. Natural history, prognostic factors and patient perceived response to treatment in chronic spontaneous urticaria. Allergy, Asthma & Clinical Immunology. 2020;16:1-11.
Cetinkaya PG, Soyer O, Esenboga S, Sahiner UM, Teksam O, Sekerel BE. Predictive factors for progression to chronicity or recurrence after the first attack of acute urticaria in preschool-age children. Allergologia et immunopathologia. 2019;47(5):484-90.
Toubi E, Vadasz Z. Predictive features associated with chronic spontaneous urticaria recurrence. The Journal of Dermatology. 2021;48(11):1786-8.
Kim JK, Har D, Brown LS, Khan DA. Recurrence of chronic urticaria: incidence and associated factors. The Journal of Allergy and Clinical Immunology: In Practice. 2018;6(2):582-5.
van der Valk PG, Moret G, Kiemeney LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol. 2002;146(1):110-3.
Beattie PE, Dawe RS, Ibbotson SH, Ferguson J. Characteristics and prognosis of idiopathic solar urticaria: a cohort of 87 cases. Archives of dermatology. 2003;139(9):1149-54.
Kulthanan K, Tuchinda P, Chularojanamontri L, Kiratiwongwan R. Cold urticaria: clinical features and natural course in a tropical country. Allergy, Asthma & Immunology Research. 2019;11(4):538-47.
Kolkhir P, Church MK, Altrichter S, Skov PS, Hawro T, Frischbutter S, et al. Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment. J Allergy Clin Immunol Pract. 2020;8(1):318-25.e5.
Grattan CE, Dawn G, Gibbs S, Francis DM. Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy. 2003;33(3):337-41.
Fok JS, Kolkhir P, Church MK, Maurer M. Predictors of treatment response in chronic spontaneous urticaria. Allergy. 2021;76(10):2965-81.
Kolkhir P, Altrichter S, Hawro T, Maurer M. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy. 2018;73(4):940-8.
Magen E, Mishal J, Zeldin Y, Feldman V, Kidon M, Schlesinger M, et al. Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. Am J Med Sci. 2010;339(6):504-8.
Kolkhir P, Muñoz M, Asero R, Ferrer M, Kocatürk E, Metz M, et al. Autoimmune chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology. 2022;149(6):1819-31.
Marzano A, Genovese G, Casazza G, Fierro M, Dapavo P, Crimi N, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. Journal of the European Academy of Dermatology and Venereology. 2019;33(5):918-24.
Ertas R, Ozyurt K, Atasoy M, Hawro T, Maurer M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy. 2018;73(3):705-12.
Asero R, Marzano AV, Ferrucci S, Cugno M. D-dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria. International Archives of Allergy and Immunology. 2017;172(1):40-4.
Kulthanan K, Subchookul C, Hunnangkul S, Chularojanamontri L, Tuchinda P. Factors predicting the response to cyclosporin treatment in patients with chronic spontaneous urticaria: a systematic review. Allergy, Asthma & Immunology Research. 2019;11(5):736-55.
Antia C, Baquerizo K, Korman A, Alikhan A, Bernstein JA. Urticaria: a comprehensive review: treatment of chronic urticaria, special populations, and disease outcomes. Journal of the American Academy of Dermatology. 2018;79(4):617-33.
Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E, Guillén-Grima F, Ferrer M. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol. 2016;175(6):1153-65.
Patruno C, Fabbrocini G, Cillo F, Torta G, Stingeni L, Napolitano M. Chronic urticaria in older adults: treatment considerations. Drugs & Aging. 2023;40(3):165-77.
Dávila I, del Cuvillo A, Mullol J, Jáuregui I, Bartra J, Ferrer M, et al. Use of second generation H1 antihistamines in special situations. J Investig Allergol Clin Immunol. 2013;23 Suppl 1:1-16.
Pratt CM, Mason J, Russell T, Reynolds R, Ahlbrandt R. Cardiovascular Safety of FexofenadineHCl. The American journal of cardiology. 1999;83(10):1451-4.
Simons F. Mizolastine: antihistaminic activity from preclinical data to clinical evaluation. Clinical & Experimental Allergy. 1999;29:3-8.
Chang TW, Wu PC, Hsu CL, Hung AF. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv Immunol. 2007;93:63-119.
Zhao ZT, Ji CM, Yu WJ, Meng L, Hawro T, Wei JF, et al. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742-50.e4.
Labrador-Horrillo M, Ferrer M. Profile of omalizumab in the treatment of chronic spontaneous urticaria. Drug Design, Development and Therapy. 2015:4909-15.
Maurer M, Rosén K, Hsieh H-J, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. New England Journal of Medicine. 2013;368(10):924-35.
Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. Journal of Allergy and Clinical Immunology. 2013;132(1):101-9.
Martina E, Damiani G, Grieco T, Foti C, Pigatto PDM, Offidani A. It is never too late to treat chronic spontaneous urticaria with omalizumab: Real‐life data from a multicenter observational study focusing on elderly patients. Dermatologic Therapy. 2021;34(2):e14841.
Nettis E, Cegolon L, Di Leo E, Canonica WG, Detoraki A, Baiardini I, et al. Omalizumab in elderly patients with chronic spontaneous urticaria: an Italian real-life experience. Annals of Allergy, Asthma & Immunology. 2018;120(3):318-23.
Kitao R, Oda Y, Washio K, Tai Y, Ono R, Nishigori C, et al. Lower efficacy of omalizumab in older adults with chronic spontaneous urticaria. The Journal of Dermatology. 2022;49(7):729-31.
Ali AK, Hartzema AG. Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting. Journal of Asthma and Allergy. 2012:1-9.
Kulthanan K, Chaweekulrat P, Komoltri C, Hunnangkul S, Tuchinda P, Chularojanamontri L, et al. Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review. J Allergy Clin Immunol Pract. 2018;6(2):586-99.
Falck P, Åsberg A, Byberg K-T, Bremer S, Bergan S, Reubsaet JL, et al. Reduced elimination of cyclosporine A in elderly (> 65 years) kidney transplant recipients. Transplantation. 2008;86(10):1379-83.
Kovarik JM, Koelle EU. Cyclosporin pharmacokinetics in the elderly. Drugs & aging. 1999;15:197-205.
Cyclosporine package insert. 19 Aug 2022. [Available from: https://www.drugs.com/pro/cyclosporine.html.
Giménez-Arnau AM, Salman A. Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress. Drugs. 2020;80(16):1617-34.
Maurer M, Khan DA, Elieh Ali Komi D, Kaplan AP. Biologics for the Use in Chronic Spontaneous Urticaria: When and Which. J Allergy Clin Immunol Pract. 2021;9(3):1067-78.
Kulthanan K, Ungprasert P, Tuchinda P, Chularojanamontri L, Rujitharanawong C, Kiratiwongwan R, et al. Symptomatic dermographism: a systematic review of treatment options. The Journal of Allergy and Clinical Immunology: In Practice. 2020;8(9):3141-61.
Kulthanan K, Hunnangkul S, Tuchinda P, Chularojanamontri L, Weerasubpong P, Subchookul C, et al. Treatments of cold urticaria: a systematic review. Journal of Allergy and Clinical Immunology. 2019;143(4):1311-31.
Magerl M, Pisarevskaja D, Staubach P, Martus P, Church M, Maurer M. Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H1‐antihistamine dose escalation. British Journal of Dermatology. 2012;166(5):1095-9.
Marsland A, Beck M. Cold urticaria responding to systemic ciclosporin. British Journal of Dermatology. 2003;149(1):214-5.
Hani N, Hartmann K, Casper C, Peters T, Schneider L-A, Hunzelmann N, et al. Improvement of cold urticaria by treatment with the leukotriene receptor antagonist montelukast. Acta dermato-venereologica. 2000;80(3).
McDonald SK, Thai KE. Danazol in the treatment of refractory acquired cold urticaria. Australasian Journal of Dermatology. 2014;55(4).
Maurer M, Altrichter S, Metz M, Zuberbier T, Church M, Bergmann K. Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. Journal of the European Academy of Dermatology & Venereology. 2018;32(3).
Gualdi G, Monari P, Rossi M, Crotti S, Calzavara‐Pinton P. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis. British Journal of Dermatology. 2012;166(6):1373-4.
Ferrucci S, Benzecry V, Berti E, Asero R. Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment. Clinical and experimental dermatology. 2020;45(3):345-6.
Bodar EJ, Simon A, de Visser M, Van Der Meer J. Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra). Neth J Med. 2009;67(9):302-5.
Lenormand C, Lipsker D. Efficiency of interleukin-1 blockade in refractory delayed-pressure urticaria. Annals of internal medicine. 2012;157(8):599-600.
Shedden C, Highet A. Delayed pressure urticaria controlled by tranexamic acid. Clinical and experimental dermatology. 2006;31(2):295-6.
Samarasinghe V, Marsland A. Class action of oral coumarins in the treatment of a patient with chronic spontaneous urticaria and delayed‐pressure urticaria. Clinical and experimental dermatology. 2012;37(7):741-3.
Magerl M, Philipp S, Manasterski M, Friedrich M, Maurer M. Successful treatment of delayed pressure urticaria with anti–TNF-α. Journal of allergy and clinical immunology. 2007;119(3):752-4.
Lyons AB, Peacock A, Zubair R, Hamzavi IH, Lim HW. Successful treatment of solar urticaria with UVA 1 hardening in three patients. Photodermatology, photoimmunology & photomedicine. 2019;35(3):193-5.
Hölzle E, Hofmann C, Plewig G. PUVA-treatment for solar urticaria and persistent light reaction. Archives of Dermatological Research. 1980;269(1):87-91.
Grundmann S, Ständer S, Luger T, Beissert S. Antihistamine combination treatment for solar urticaria. British Journal of Dermatology. 2008;158(6):1384-6.
Levi A, Enk CD. Treatment of solar urticaria using antihistamine and leukotriene receptor antagonist combinations tailored to disease severity. Photodermatology, Photoimmunology & Photomedicine. 2015;31(6):302-6.
Mang R, Stege H, Budde MA, Ruzicka T, Krutmann J. Successful treatment of solar urticaria by extracorporeal photochemotherapy (photopheresis)–a case report. Photodermatology, Photoimmunology & Photomedicine. 2002;18(4):196-8.
Aubin F, Porcher R, Jeanmougin M, Léonard F, Bedane C, Moreau A, et al. Severe and refractory solar urticaria treated with intravenous immunoglobulins: a phase II multicenter study. Journal of the American Academy of Dermatology. 2014;71(5):948-53. e1.
Haylett A, Nie Z, Brownrigg M, Taylor R, Rhodes L. Systemic photoprotection in solar urticaria with α‐melanocyte‐stimulating hormone analogue [Nle4‐D‐Phe7]‐α‐MSH. British Journal of Dermatology. 2011;164(2):407-14.
Bissonnette R, Buskard N, McLean DI, Lui H. Treatment of refractory solar urticaria with plasma exchange. Journal of cutaneous medicine and surgery. 1999;3(5):236-8.
Kulthanan K, Ungprasert P, Tapechum S, Rujitharanawong C, Kiratiwongwan R, Munprom K, et al. Vibratory angioedema subgroups, features, and treatment: results of a systematic review. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(2):971-84.
Kulthanan K, Ungprasert P, Tuchinda P, Chularojanamontri L, Charoenpipatsin N, Maurer M. Delayed pressure urticaria: a systematic review of treatment options. The Journal of Allergy and Clinical Immunology: In Practice. 2020;8(6):2035-49. e5.
Pezzolo E, Peroni A, Gisondi P, Girolomoni G. Heat urticaria: a revision of published cases with an update on classification and management. British Journal of Dermatology. 2016;175(3):473-8.
McSweeney SM, Christou EA, Maurer M, Grattan CE, Tziotzios C, McGrath JA. Physical urticaria: Clinical features, pathogenesis, diagnostic work-up, and management. Journal of the American Academy of Dermatology. 2023;89(2):324-37.
